Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;35(6):1820-1822.
doi: 10.1038/s41375-021-01288-0. Epub 2021 May 18.

Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients

Nikolay Mayanskiy  1 , Polina Luchkina  2 , Natalia Fedorova  2 , Yuri Lebedin  3 , Natalia Ponomareva  2
Affiliations
Comment

Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients

Nikolay Mayanskiy et al. Leukemia. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

YL is an employee of XEMA Company. All other authors have no competing interests

Figures

Fig. 1
Fig. 1. Dynamics and magnitude of the anti-SARS-CoV-2 antibody response in pediatric oncology patients, by week after a positive PCR test for SARS-CoV-2.
A The dynamics of the anti-SARS-CoV-2 IgG and IgM antibody seroprevalence rate was examined in 133 serum specimens obtained at the indicated time points from 18 pediatric oncology patients after a SARS-CoV-2 PCR-positive test. At week 18, only IgG antibodies were analyzed. The level of anti-RBD (B) and anti-N (C) IgG antibodies are depicted as median (Me) positivity indexes (PI) representing the ratio between the specimen and the internal cut-off control optical density in the ELISA assay. Error bars indicate interquartile ranges (IQR). Dashed lines on (B and C) show the positivity threshold. The actual number of specimens analyzed by time points is given in Supplementary Table 2.
See this image and copyright information in PMC

Comment on

References

    1. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047–3049. doi: 10.1038/s41375-020-01030-2. - DOI - PMC - PubMed
    1. O’Nions J, Muir L, Zheng J, Rees-Spear C, Rosa A, Roustan C, et al. SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia. 2021;35:289–292. doi: 10.1038/s41375-020-01103-2. - DOI - PMC - PubMed
    1. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22:25–31. doi: 10.1038/s41590-020-00826-9. - DOI - PMC - PubMed
    1. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12:1813. doi: 10.1038/s41467-021-22034-1. - DOI - PMC - PubMed
    1. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, Juárez-Villegas L, Márquez-González H. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2021;10:608282. doi: 10.3389/fonc.2020.608282. - DOI - PMC - PubMed